India's Natco Pharma will acquire significant stakes in 135-year-old South African pharmaceutical giant Adcock Ingram. The R 4.2-billion deal will see Adcock Ingram becoming a privately-held entity co-owned by Natco and Bidvest, which will remain the majority shareholder in the group. A meeting of shareholders of Adcock Ingram approved Natco's proposal to acquire all the ordinary shares in the company.Also read Natco made a firm offer in July this year, the company announced in a statement on the Johannesbu ...

Core Points - The United Kingdom is set to offer Americans significant discounts on prescription drugs, implementing a "most favored nation" pricing clause, which means Americans will pay the lowest price available globally [1] - AstraZeneca has committed to providing all prescription medications to Medicaid at these most favored nation prices, potentially saving American taxpayers hundreds of millions of dollars annually [6] - AstraZeneca will also invest $50 billion in the U.S. over the next five years for drug research and development, as well as onshore manufacturing facilities, creating approximately 3,600 jobs [11] Company and Industry Summary - Americans have historically paid the highest prices for prescription drugs compared to other countries, prompting the need for reforms [5] - The announcement includes a specific example of a 654% price reduction for certain inhalers and diabetic medications, indicating substantial potential savings for consumers [9] - AstraZeneca's commitment to list popular drugs online at a dedicated website further enhances transparency and accessibility for consumers [8] - The investment in U.S. manufacturing and R&D by AstraZeneca aligns with broader efforts to lower healthcare costs and improve drug availability [11][15]

U.S. President Donald Trump announced an agreement with AstraZeneca on Friday where the drugmaker will offer its catalog of prescription drugs to the United States at a discounted price. ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider McKesson (MCK) . This company, which is in the Zacks Medical - Dental Supplies industry, shows potential for another earnings beat.When looking at the last two reports, this prescription drug distributor has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 1.76%, on average, in the ...

We recently published 11 Stocks Crushing Wall Street With Whopping Gains. Pfizer Inc. (NYSE:PFE) is one of the top performers on Tuesday. Pfizer Inc. extended its winning streak to a third straight day on Tuesday, jumping 6.83 percent to close at $25.48 apiece as investors cheered its exception from the US government’s imposition of 100 percent tariffs on pharmaceutical imports. In a statement, Pfizer Inc. (NYSE:PFE) said it reached a landmark agreement with the US government to lower prescription drug c ...

Group 1: Pharmaceutical Industry - The U.S. administration reached a deal with Pfizer, where the company agreed to lower some drug prices and invest $70 billion in U.S. manufacturing and R&D in exchange for a three-year exemption from proposed tariffs on imported prescription drugs [2][4] - Pfizer's stock surged by 6.83% to close at $25.48 on September 30, 2025, with trading volume reaching over 153 million shares, nearly 3.5 times its usual average [3] - Other pharmaceutical companies, including Johnson & Johnson and Eli Lilly, also saw stock price increases following the announcement, indicating a positive market sentiment towards the sector [3] Group 2: Tariff Impacts on Various Industries - President Trump announced a 100% tariff on foreign-made films, which initially caused a slight dip in U.S. studio stocks, but they rebounded quickly, indicating investor adaptation to such announcements [5][6] - A 10% import tax on softwood lumber and new 25% tariffs on heavy trucks were introduced, with Ford Motor Co. initially seeing a stock increase but later facing criticism from its CEO regarding the tariffs' negative impact on future investments [7] - The overall market reaction to these tariffs has been mixed, with some sectors experiencing volatility while others showed resilience [6][7] Group 3: Government Shutdown Effects - The U.S. government entered a partial shutdown on October 1, 2025, which raised concerns about delays in critical economic data releases [8][9] - Market reactions were varied, with initial declines in stock futures but a surprising resilience in major indices by midday, showcasing the market's ability to absorb political uncertainty [10][11] - Analysts suggested that the impact of the shutdown would be limited unless prolonged, indicating a potential for short-term volatility rather than long-term consequences [12] Group 4: Overall Market Sentiment - The recent events illustrate the "Trump effect" on financial markets, where policy announcements create immediate but often unpredictable market reactions [13][14] - Companies like Pfizer are navigating a landscape where tariff threats can lead to strategic opportunities, while other industries are left to assess the long-term implications of sudden protectionist measures [13][14] - The market has shown a remarkable tolerance for political volatility, oscillating between dips and rebounds, indicating an adaptation to the current political climate [14]

Key Points Pfizer signed a deal with the White House to help Americans pay lower prices for prescription drugs. This agreement removes the uncertainty hanging over Pfizer's head related to the Trump administration's policies. However, Pfizer will slash its drug prices for many products. 10 stocks we like better than Pfizer › Pfizer (NYSE: PFE) announced on Tuesday that it had signed an agreement with the White House that will help Americans pay lower prices for prescription drugs and bolster U.S. ...

A Labor Department report released on Tuesday showed that the U.S. JOLTs job openings rose to 7.227 million in August, stronger than expectations of 7.190 million. Also, the U.S. July S&P/CS HPI Composite - 20 n.s.a. eased to +1.8% y/y from +2.2% y/y in June (revised from +2.1% y/y), stronger than expectations of +1.7% y/y. At the same time, the U.S. Conference Board’s consumer confidence index fell to a 5-month low of 94.2 in September, weaker than expectations of 96.0. In addition, the U.S. Chicago PMI un ...

Group 1: European Market Overview - European stocks showed mixed performance as the U.S. faced a government shutdown after the Senate failed to pass a short-term spending bill [1] - The pan-European Stoxx 600 index increased by 0.2 percent to 559.42, following a 0.5 percent rise on Tuesday [1] Group 2: National Indices Performance - The German DAX decreased by 0.2 percent, while France's CAC 40 saw a slight decline [2] - The U.K.'s FTSE 100 rose by 0.7 percent, supported by a survey indicating accelerated growth in U.K. house prices [2] Group 3: Housing Market Insights - U.K. house prices experienced an annual growth of 2.2 percent in September, up from 2.1 percent in the previous month, surpassing the forecast of 1.8 percent [2] - On a monthly basis, house prices rebounded by 0.5 percent after a 0.1 percent decline in August, exceeding economists' expectations of a 0.2 percent increase [3] Group 4: Pharmaceutical Sector Developments - Pharmaceutical stocks gained traction as Pfizer secured a deal with the U.S. government to reduce prescription drug prices in exchange for tariff relief [3] - Notable stock movements included Sartorius rising by 6.7 percent, Merck increasing by 5.2 percent, and Roche jumping by 5.3 percent [3] Group 5: Company-Specific News - Tate & Lyle, Plc saw a significant drop of almost 10 percent after revising its revenue and EBITDA outlook for the fiscal year ending March 31 [4] - Vallourec's shares increased by 2.2 percent following a new order from Petrobras for over 30 units of its Oil Country Tubular Goods solution [4] - British bakery chain Greggs surged by 8.2 percent, reporting a 6.1 percent sales growth for the third quarter of 2025 [5] - Technip Energies gained 1 percent after securing two engineering contracts from Repsol for the Ecoplanta project [5] - Diageo's stock rose by about 2 percent after pricing €1 billion of fixed-rate bonds under its European Debt Issuance Program [5] - Dutch engineering consultancy Arcadis surged by 8 percent due to share buyback announcements [6]

European healthcare stocks jumped on Wednesday, a day after Pfizer and U.S. President Donald Trump said the U.S.-based drugmaker agreed to lower prescription drug prices in the Medicaid program in exchange for tariff relief. ...